Interindividual Variability in Cytochrome P450–Mediated Drug Metabolism

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Drug Metabolism And Disposition

• Publication date

  2016-03-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1124/dmd.115.067900PMID 26681736PMCID PMC4767386
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Farnesoid X Receptor Agonist Represses Cytochrome P450 2D6 Expression by Upregulating Small Heterodimer Partner

  2015influential reference
• The CYP 2 C 19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP 2 C 19 * 35 and CYP 2 C 19 * 2 Alleles s

  2015cited by this paper
• Dose of Phenobarbital and Age of Treatment at Early Life are Two Key Factors for the Persistent Induction of Cytochrome P450 Enzymes in Adult Mouse Liver

  2015cited by this paper
• Estrogen-induced cholestasis leads to repressed CYP 2 D 6 expression in CYP 2 D 6-humanized mice

  2015cited by this paper
• The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C19*35 and CYP2C19*2 Alleles

  2015cited by this paper
• Estrogen-Induced Cholestasis Leads to Repressed CYP2D6 Expression in CYP2D6-Humanized Mice

  2015cited by this paper
• Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis

  2014cited by this paper
• Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies

  2014cited by this paper
• 6β-Hydroxycortisol Is an Endogenous Probe for Evaluation of Drug–Drug Interactions Involving a Multispecific Renal Organic Anion Transporter, OAT3/SLC22A8, in Healthy Subjects

  2014cited by this paper
• Bile Acid Signaling in Metabolic Disease and Drug Therapy

  2014cited by this paper
• microRNA-34a is associated with expression of key hepatic transcription factors and cytochromes P450.

  2014cited by this paper
• Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics.

  2014influential reference
• Profound reduction in the tamoxifen active metabolite endoxifen in a patient on phenytoin for epilepsy compared with a CYP2D6 genotype matched cohort.

  2014cited by this paper
• Comparison of two endogenous biomarkers of CYP3A4 activity in a drug–drug interaction study between midostaurin and rifampicin

  2014cited by this paper
• Altered Expression of Small Heterodimer Partner Governs Cytochrome P450 (CYP) 2D6 Induction during Pregnancy in CYP2D6-humanized Mice*

  2013influential reference
• Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy.

  2013cited by this paper
• Genetic Variation in Aldo-Keto Reductase 1D1 (AKR1D1) Affects the Expression and Activity of Multiple Cytochrome P450s

  2013cited by this paper
• Nuclear receptors PXR and CAR: implications for drug metabolism regulation, pharmacogenomics and beyond

  2013cited by this paper
• Potential role of CYP2D6 in the central nervous system

  2013cited by this paper
• Evaluation of Endogenous Metabolic Markers of Hepatic CYP3A Activity Using Metabolic Profiling and Midazolam Clearance

  2013influential reference
• Global metabolomics and targeted steroid profiling reveal that rifampin, a strong human PXR activator, alters endogenous urinary steroid markers.

  2013cited by this paper
• Genetic variation in Aldo-keto reductase 1 D 1 ( AKR 1 D 1 ) affects the expression and activity of multiple Cytochrome P 450 s ( CYPs )

  2013cited by this paper
• Oxysterols and Parkinson's disease: evidence that levels of 24S-hydroxycholesterol in cerebrospinal fluid correlates with the duration of the disease.

  2013cited by this paper
• An Inducible Cytochrome P450 3A4-Dependent Vitamin D Catabolic Pathway

  2012cited by this paper
• Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects

  2012cited by this paper
• Targeted profiling of circulating and hepatic bile acids in human, mouse, and rat using a UPLC-MRM-MS-validated method[S]

  2012cited by this paper
• Neonatal activation of the nuclear receptor CAR results in epigenetic memory and permanent change of drug metabolism in mouse liver

  2012cited by this paper
• RNA Sequencing Reveals Dynamic Changes of mRNA Abundance of Cytochromes P450 and Their Alternative Transcripts during Mouse Liver Development

  2012cited by this paper
• Estimation of Drug-Metabolizing Capacity by Cytochrome P450 Genotyping and Expression

  2012cited by this paper
• Evaluation of 6β‐Hydroxycortisol, 6β‐Hydroxycortisone, and a Combination of the Two as Endogenous Probes for Inhibition of CYP3A4 In Vivo

  2011cited by this paper
• Quantification of 4-beta-hydroxycholesterol in human plasma using automated sample preparation and LC-ESI-MS/MS analysis.

  2011influential reference
• Anandamide Oxidation by Wild-Type and Polymorphically Expressed CYP 2 B 6 and CYP 2 D 6

  2011cited by this paper
• Prediction of variability in CYP3A4 induction using a combined 1H NMR metabonomics and targeted UPLC-MS approach.

  2011cited by this paper
• Anandamide Oxidation by Wild-Type and Polymorphically Expressed CYP2B6 and CYP2D6

  2011cited by this paper
• Retinoic acid represses CYP7A1 expression in human hepatocytes and HepG2 cells by FXR/RXR-dependent and independent mechanisms

  2010cited by this paper
• Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver.

  2010influential reference
• Genetic Predictors of Interindividual Variability in Hepatic CYP3A4 Expression

  2010cited by this paper
• 4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin.

  2009cited by this paper
• A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose

  2009cited by this paper
• Comparison of the Pharmacokinetics of Venlafaxine Extended Release and Desvenlafaxine in Extensive and Poor Cytochrome P450 2D6 Metabolizers

  2009cited by this paper
• Evaluation of CYP3A activity in humans using three different parameters based on endogenous cortisol metabolism

  2009influential reference
• Genetic predictors of inter-individual variability in hepatic CYP 3 A 4 expression

  2009cited by this paper
• Dynamic Patterns of Histone Methylation Are Associated with Ontogenic Expression of the Cyp3a Genes during Mouse Liver Maturation

  2009cited by this paper
• Endogenous cortisol 6 beta-hydroxylation clearance is not an accurate probe for overall cytochrome P450 3A phenotyping in humans.

  2009cited by this paper
• Human hepatic CYP2B6 developmental expression: the impact of age and genotype.

  2009influential reference
• The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype

  2008cited by this paper
• Cytochrome p450 and chemical toxicology.

  2008cited by this paper
• The Endocannabinoid Anandamide Is a Substrate for the Human Polymorphic Cytochrome P450 2D6

  2008cited by this paper
• A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.

  2008cited by this paper
• Changes in maternal liver Cyp2c and Cyp2d expression and activity during rat pregnancy.

  2008cited by this paper
• Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism

  2008cited by this paper
• Regulation of hepatocyte nuclear factor 4 alpha-mediated transcription.

  2008influential reference
• Novel Single Nucleotide Polymorphisms in the Promoter and Intron 1 of Human Pregnane X Receptor/NR1I2 and Their Association with CYP3A4 Expression

  2008cited by this paper
• Determination of bile acids in human serum by on-line restricted access material-ultra high-performance liquid chromatography-mass spectrometry.

  2008cited by this paper
• Regulation of Hepatocyte Nuclear Factor 4α-mediated Transcription

  2008cited by this paper
• Ontogeny of human hepatic cytochromes P450

  2007influential reference
• CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children

  2007influential reference
• New perspectives on the impact of cytochrome P450 3A expression for pediatric pharmacology.

  2006cited by this paper
• Poor correlation between 6beta-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity.

  2006cited by this paper
• Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy.

  2005cited by this paper
• Predicting in vivo drug interactions from in vitro drug discovery data

  2005cited by this paper
• Induction of Human CYP2C9 by Rifampicin, Hyperforin, and Phenobarbital Is Mediated by the Pregnane X Receptor

  2004cited by this paper
• Control of Pancreas and Liver Gene Expression by HNF Transcription Factors

  2004cited by this paper
• Developmental Expression of Human Hepatic CYP2C9 and CYP2C19

  2004cited by this paper
• Urinary 6β-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals

  2003cited by this paper
• Hepatic CYP2B6 Expression: Gender and Ethnic Differences and Relationship to CYP2B6 Genotype and CAR (Constitutive Androstane Receptor) Expression

  2003cited by this paper
• Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6.

  2003cited by this paper
• Coordinated intrahepatic and extrahepatic regulation of cytochrome P4502D6 in healthy subjects and in patients after liver transplantation

  2003influential reference
• Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase.

  2003cited by this paper
• Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.

  2003influential reference
• Induction of Drug Metabolism: The Role of Nuclear Receptors

  2003cited by this paper
• Phenobarbital-Imprinted Overinduction of Adult Constituent CYP Isoforms

  2003cited by this paper
• Developmental Expression of Human Hepatic CYP 2 C 9 and CYP 2 C 19

  2003cited by this paper
• G enetic contribution to variable human CYP 3 A-mediated metabolism

  2002cited by this paper
• Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.

  2002cited by this paper
• Genetic contribution to variable human CYP3A-mediated metabolism.

  2002cited by this paper
• Nutritional assessment of serum and hepatic vitamin A levels in patients with cirrhosis.

  2001cited by this paper
• The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse.

  2001influential reference
• Interindividual variability in inhibition and induction of cytochrome P450 enzymes.

  2001cited by this paper
• Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6.

  2001cited by this paper
• Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor.

  2001cited by this paper
• Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

  2001cited by this paper
• The CYP 2 D 6 Humanized Mouse : Effect of the Human CYP 2 D 6 Transgene and HNF 4 on the Disposition of Debrisoquine in the Mouse

  2001influential reference
• Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4.

  2001cited by this paper
• Identification of a chemical tool for the orphan nuclear receptor FXR.

  2000cited by this paper
• A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis.

  2000cited by this paper
• Circadian variation of the urinary 6β-hydroxycortisol to cortisol ratio that would reflect hepatic CYP3A activity

  2000cited by this paper
• The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module.

  1999influential reference
• Bile acids: natural ligands for an orphan nuclear receptor.

  1999influential reference
• Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region.

  1999cited by this paper
• The Repressed Nuclear Receptor CAR Responds to Phenobarbital in Activating the Human CYP2B6 Gene*

  1999cited by this paper
• Human CYP2B6: expression, inducibility and catalytic activities.

  1999influential reference
• Inhibition and Induction of Cytochrome P450 and the Clinical Implications

  1998cited by this paper
• Expression of CYP3A in the human liver--evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth.

  1997cited by this paper
• Induction of CYP2D6 in pregnancy

  1997cited by this paper
• Genetic association between sensitivity to warfarin and expression of CYP2C9*3.

  1997cited by this paper
• Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.

  1997cited by this paper
• Characterization of the Human Cytochrome P4502D6 Promoter

  1996cited by this paper
• The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.

  1994cited by this paper
• Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population

  1992influential reference

• ADME profile of phencyclidine (PCP) analogues: emerging dissociative hallucinogens 3-MeO-PCP (CAS: 72242-03-6) and 4-MeO-PCP (CAS: 2201-35-6)-a multi-in silico approach for comprehensive prediction of absorption, distribution, metabolism and excretion relevant to clinical and forensic toxicology.

  2026cites this paper
• Mechanism-Aware Foundation Models in Drug Discovery: From Molecular Representation to Biological Translation

  2026cites this paper
• Phase I Metabolism of Tiletamine in Human Liver Microsomes and Its Detection in Human Specimens (Urine and Hair)

  2026cites this paper
• Effects of Crocus sativus and its active constituents on cytochrome P450: a review

  2025cites this paper
• Systematic Investigation of CYP3A4 Using Side-by-Side Comparisons of Apo, Active Site, and Allosteric-Bound States.

  2025cites this paper
• Review on Traditional Chinese Medicine-Induced Liver Injury.

  2025cites this paper
• Impact of variation in CYP3A and CYP2C8 on tucatinib metabolic clearance in human liver microsomes.

  2025cites this paper
• Metabolically purified human stem cell-derived hepatocytes reveal distinct effects of Ebola and Lassa viruses

  2025cites this paper
• Gene expression profiling reveals enhanced nutrient and drug metabolism and maturation of hiPSC-derived intestine-on-chip relative to organoids and Transwells

  2025cites this paper
• Characterization of small molecule drug clearance mechanisms using in vitro and in vivo approaches in drug discovery and development

  2025cites this paper
• Effects of Genetic Polymorphisms of CYP450 Enzymes on Blood Hydroxychloroquine Levels and Clinical Response Among Patients With Cutaneous Lupus Erythematosus.

  2025cites this paper
• A Review on New Frontiers in Drug-Drug Interaction Predictions and Safety Evaluations with In Vitro Cellular Models

  2025cites this paper
• Comprehensive identification and characterization of in vitro and in vivo metabolites of the novel GLP-1 receptor agonist danuglipron using UHPLC-QToF-MS/MS.

  2025cites this paper
• Inter-individual variability, differential tissue abundance, and sub-cellular localization of human aldo-keto reductases (AKRs) and hydroxy-steroid dehydrogenases (HSDs).

  2025cites this paper
• Editorial for the Special Issue “Cytochrome P450 (CYP) in Health and Disease”

  2025cites this paper
• 1H NMR spectroscopic characterisation of HepG2 cells as a model metabolic system for toxicology studies.

  2024cites this paper
• Advancing understanding of human variability through toxicokinetic modeling, in vitro-in vivo extrapolation, and new approach methodologies

  2024cites this paper
• A Comparison of Molecular Techniques for Improving the Methodology in the Laboratory of Pharmacogenetics

  2024cites this paper
• Genetic ancestry in population pharmacogenomics unravels distinct geographical patterns related to drug toxicity

  2024cites this paper
• The Impact of CYP 2C9 rs1799853 and rs1057910 Polymorphism on Plasma Losartan Metabolic Ratio in a Sample of Iraqi Hypertensive Patients

  2024cites this paper
• Meta‐Analysis of Noncompartmental Pharmacokinetic Parameters to Evaluate the Impact of CYP2C19 and CYP2C9 Genetic Polymorphisms on Abrocitinib Exposure

  2024cites this paper
• Methyltransferase Like-3–Mediated N6-Methyladenosine Modification of Long Noncoding RNA Hepatocyte Nuclear Factor 1a Antisense RNA 1/Hepatocyte Nuclear Factor 4a Antisense RNA 1 Regulates Cytochrome P450 Enzyme Expression

  2024cites this paper
• Hepatic Metabolic Enzyme Activity with Endogenous Substances-current Status, Challenges and Limitations.

  2024cites this paper
• Intestine-on-chip enhances nutrient and drug metabolism and maturation of iPSC-derived intestinal epithelial cells relative to organoids and Transwells

  2024cites this paper
• Potential of pharmacogenetics in minimizing drug therapy problems in cystic fibrosis.

  2024cites this paper
• Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: Focus on antipsychotics

  2024cites this paper
• Occurrence of the two major regulated mycotoxins, ochratoxin A and fumonisin B1, in cereal and cereal-based products in Europe and toxicological effects: a review.

  2024cites this paper
• The Association Between Antidepressant Use and Drug-Induced Liver Injury: A Nationwide, Population-Based Case–Control Study in Taiwan

  2024cites this paper
• Cellular pharmacokinetic of methotrexate and its modulation by folylpolyglutamate synthetase and γ-glutamyl hydrolase in tumor cells

  2024cites this paper
• Hallmarks of cancer resistance

  2024cites this paper
• Validation of a bupropion, dextromethorphan, and omeprazole cocktail for simultaneous phenotyping of cytochrome P450 2B11, 2D15, and 3A12 activities in dogs.

  2024cites this paper
• STRUCTURAL POLYMORPHISM OF CYP2D6 AND CYP2C19 GENES MODIFIES THE EFFICACY AND TOXICITY OF PHARMACOTHERAPY FOR DEPRESSIVE STATES

  2024cites this paper
• Probing Liver Injuries Induced by Thioacetamide in Human In Vitro Pooled Hepatocyte Experiments

  2024cites this paper
• Roles of Breast Cancer Resistance Protein and Organic Anion Transporting Polypeptide 2B1 in Gastrointestinal Toxicity Induced by SN-38 under Inflammatory Conditions.

  2024cites this paper
• Asia‐Inclusive Global Development of Enpatoran: Results of an Ethno‐Bridging Study, Intrinsic/Extrinsic Factor Assessments and Disease Trajectory Modeling to Inform Design of a Phase II Multiregional Clinical Trial

  2024cites this paper
• Computational prediction for designing novel ketonic derivatives as potential inhibitors for breast cancer: A trade-off between drug likeness and inhibition potency

  2024cites this paper
• Special Section on Perspective on Drug Metabolism and Disposition, Part I — Minireview Epigenetic Mechanisms Contribute to Intraindividual Variations of Drug Metabolism Mediated by Cytochrome P450 Enzymes

  2023cites this paper
• Whole blood hydroxychloroquine: Does genetic polymorphism of cytochrome P450 enzymes have a role?

  2023cites this paper
• CONTROL OF THE PHARMACOGENETICS OF ENZYMES’ MEDICINE BIOTRANSFORMATION – A TOOL FOR PROVIDING PERSONALIZED MEDICINE

  2023cites this paper
• Impact of Obesity and Bariatric Surgery on Metabolic Enzymes and P-Glycoprotein Activity Using the Geneva Cocktail Approach

  2023cites this paper
• Sesquiterpene Lactones as Potential Cyclin B1/CDK1 Complex Inhibitors

  2023cites this paper
• Novel Approaches to Characterize Individual Drug Metabolism and Advance Precision Medicine

  2023cites this paper
• Sex- and Lifestyle-Related Factors are Associated with Altered Hepatic CYP Protein Levels in People Diagnosed with Mental Disorders

  2023cites this paper
• Impact of Cytochrome P450 Enzymes on the Phase I Metabolism of Drugs

  2023cites this paper
• Epigenetic Mechanisms Contribute to Intraindividual Variations of Drug Metabolism Mediated by Cytochrome P450 Enzymes

  2023cites this paper
• Prenatal Lipopolysaccharide Exposure Alters Hepatic Drug-Metabolizing Enzyme Expression in Mouse Offspring via Histone Modifications

  2023cites this paper
• Investigating bile acid-mediated cholestatic drug-induced liver injury using a mechanistic model of multidrug resistance protein 3 (MDR3) inhibition

  2023cites this paper
• Pharmacokinetic and Pharmacodynamic Considerations of Antibiotic Use in Neonates

  2023cites this paper
• Novel Independent Trans- and Cis-Genetic Variants Associated with CYP2D6 Expression and Activity in Human Livers

  2023cites this paper
• Structural activity, spectroscopic, Fukui, NCI, AIM, IGM combined with molecular docking and molecular dynamics simulation on 4-methylpyridinium 4-hydroxybenzoate-potent drug anti-leukemia cancer

  2023cites this paper
• Inter-individual variation in chlorpyrifos toxicokinetics characterized by physiologically based kinetic (PBK) and Monte Carlo simulation comparing human liver microsome and Supersome™ cytochromes P450 (CYP)-specific kinetic data as model input

  2022cites this paper
• Ten Years of Experience Support Pharmacogenetic Testing to Guide Individualized Drug Therapy

  2022cites this paper
• In vitro–in silico-based prediction of inter-individual and inter-ethnic variations in the dose-dependent cardiotoxicity of R- and S-methadone in humans

  2022cites this paper
• Ways to Improve Insights into Clindamycin Pharmacology and Pharmacokinetics Tailored to Practice

  2022cites this paper
• Special Section on Drug Metabolism in Liver Injury and Repair Long Noncoding RNAs Hepatocyte Nuclear Factor 4A Antisense RNA 1 and Hepatocyte Nuclear Factor 1A Antisense RNA 1 Are Involved in Ritonavir-Induced Cytotoxicity in Hepatoma Cells

  2022cites this paper
• Possible Mechanisms of the Interplay between Drugs and Mycotoxins—Is There a Possible Impact?

  2022cites this paper
• Effect of pharmacogenomic testing on pediatric mental health outcome: a 6-month follow-up.

  2022cites this paper
• Cytochromes P450 and P-Glycoprotein Phenotypic Assessment to Optimize Psychotropic Pharmacotherapy: A Retrospective Analysis of Four Years of Practice in Psychiatry

  2022cites this paper
• Variations in the Frequencies of Polymorphisms in the CYP450s Genes in Eight Major Ethnicities of Iran: A Review of the Human Data

  2022cites this paper
• The Role of CYP3A in Health and Disease

  2022cites this paper
• The Effect of Menopause on Antipsychotic Response

  2022cites this paper
• Prediction of pyrotinib exposure based on physiologically-based pharmacokinetic model and endogenous biomarker

  2022cites this paper
• MDN1 Mutation Is Associated With High Tumor Mutation Burden and Unfavorable Prognosis in Breast Cancer

  2022cites this paper
• Unravelling the pharmacokinetics of aflatoxin B1: In vitro determination of Michaelis–Menten constants, intrinsic clearance and the metabolic contribution of CYP1A2 and CYP3A4 in pooled human liver microsomes

  2022cites this paper
• Pharmacogenetics of the cytochromes P450: Selected pharmacological and toxicological aspects.

  2022cites this paper
• Seasonal but not sex-biased gene expression of the carotenoid ketolase, CYP2J19, in the sexually dichromatic southern red bishop (Euplectes orix)

  2022cites this paper
• Physiologically based pharmacokinetic modeling of brivaracetam and its interactions with rifampin based on CYP2C19 phenotypes.

  2022cites this paper
• Interplay of Vitamin D and CYP3A4 Polymorphisms in Endocrine Disorders and Cancer

  2022cites this paper
• Frequency of Important CYP450 Enzyme Gene Polymorphisms in the Iranian Population in Comparison with Other Major Populations: A Comprehensive Review of the Human Data

  2021cites this paper
• Inhibition and Induction by Poziotinib of Different Rat Cytochrome P450 Enzymes In Vivo and in an In Vitro Cocktail Method

  2021cites this paper
• Exploring the new potential antiviral constituents of Moringa oliefera for SARS-COV-2 pathogenesis: An in silico molecular docking and dynamic studies

  2021cites this paper
• The 1β-Hydroxy-Deoxycholic Acid to Deoxycholic Acid Urinary Metabolic Ratio: Toward a Phenotyping of CYP3A Using an Endogenous Marker?

  2021cites this paper
• Sex- and Gender-Based Pharmacological Response to Drugs

  2021cites this paper
• Physiologically based kinetic modelling based prediction of in vivo rat and human acetylcholinesterase (AChE) inhibition upon exposure to diazinon

  2021cites this paper
• The vocal tract as a time machine: inferences about past speech and language from the anatomy of the speech organs

  2021cites this paper
• Hepatic Cytochrome P450 Abundance and Activity in the Developing and Adult Göttingen Minipig: Pivotal Data for PBPK Modeling

  2021cites this paper
• Han Chinese specific cytochrome P450 polymorphisms and their impact on the metabolism of anti-hypertensive drugs with adrenoreceptor blocking properties

  2021cites this paper
• Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants

  2021cites this paper
• Flavonoids as potential anti-platelet aggregation agents: from biochemistry to health promoting abilities

  2021cites this paper
• Chronic Inflammatory Status Observed in Patients with Type 2 Diabetes Induces Modulation of Cytochrome P450 Expression and Activity

  2021cites this paper
• Interactions between cardiology and oncology drugs in precision cardio-oncology.

  2021cites this paper
• A PRELIMINARY STUDY ON CYTOCHROME 2E1 GENE SINGLE NUCLEOTIDE POLYMORPHISMS AMONG ETHNIC FULANI IN NORTH WESTERN NIGERIA

  2021cites this paper
• Human variability in polymorphic CYP2D6 metabolism: Implications for the risk assessment of chemicals in food and emerging designer drugs.

  2021cites this paper
• ZnT8 Deficiency Protects From APAP-Induced Acute Liver Injury by Reducing Oxidative Stress Through Upregulating Hepatic Zinc and Metallothioneins

  2021cites this paper
• OpenCYP: An open source database exploring human variability in activities and frequencies of polymophisms for major cytochrome P-450 isoforms across world populations.

  2021cites this paper
• Comprehensive Gut Microbiota and Drug Processing

  2021cites this paper
• Rapid in-plate screening of biotransformation products in single zebrafish embryos

  2021cites this paper
• The Person’s Care Requires a Sex and Gender Approach

  2021cites this paper
• Insights into Weak and Covalent interactions, Reactivity sites and Pharmacokinetic Studies of 4-Dimethylaminopyridinium Salicylate Monohydrate using Quantum Chemical Computation Method

  2021cites this paper
• Utility, promise, and limitations of liquid chromatography‐mass spectrometry‐based therapeutic drug monitoring in precision medicine

  2021cites this paper
• Interindividual Variability of Cytochromes P450 2B Mediated Oxidation in Human Liver

  2021cites this paper
• Scientific Opinion of the Scientific Panel on Plant Protection Products and their Residues (PPR Panel) on testing and interpretation of comparative in vitro metabolism studies

  2021cites this paper
• Long Noncoding RNAs Hepatocyte Nuclear Factor 4A Antisense RNA 1 and Hepatocyte Nuclear Factor 1A Antisense RNA 1 Are Involved in Ritonavir-Induced Cytotoxicity in Hepatoma Cells

  2021cites this paper
• The Role of CYP450 Drug Metabolism in Precision Cardio-Oncology

  2020influential citation
• Physiologically based pharmacokinetic modeling of tramadol to inform dose adjustment and drug‐drug interactions according to CYP2D6 phenotypes

  2020cites this paper
• Pharmacokinetic-Pharmacodynamic Modeling of the Antioxidant Activity of Quzhou Fructus Aurantii Decoction in a Rat Model of Hyperlipidemia.

  2020cites this paper
• Pediatric pharmacogenomics: challenges and opportunities: on behalf of the Sanford Children’s Genomic Medicine Consortium

  2020cites this paper
• Cytochrome P450-mediated estrogen catabolism therapeutic avenues in epilepsy

  2020cites this paper
• Pharmacogenomics of anticancer drugs: Personalising the choice and dose to manage drug response

  2020cites this paper
• Strain-Dependent Variability of Early Discovery Small Molecule Pharmacokinetics in Mice: Does Strain Matter?

  2020cites this paper